3D打印相关业务
Search documents
哈森商贸(中国)股份有限公司股票交易异常波动公告
Shang Hai Zheng Quan Bao· 2026-01-29 20:26
Core Viewpoint - The stock of Hasen Trading (China) Co., Ltd. experienced an abnormal trading fluctuation, with a cumulative closing price increase of 20% over two consecutive trading days, triggering the abnormal fluctuation standards set by the Shanghai Stock Exchange [2][5]. Group 1: Stock Trading Abnormality - The company's stock price increased by a cumulative 20% on January 28 and 29, 2026, which is classified as an abnormal trading fluctuation according to the Shanghai Stock Exchange rules [2][5]. - The company conducted a self-examination and confirmed that there are no undisclosed significant matters affecting the stock price, aside from publicly disclosed information [2][7]. Group 2: Business Operations - The company reported that its daily operations are normal, with no significant changes in market conditions or production costs [6]. - There are no major undisclosed events that could impact the stock price, including significant asset restructuring or major transactions [7][9]. Group 3: Financial Performance and Risks - The company anticipates a net loss attributable to shareholders of between 24 million and 36 million yuan for the fiscal year 2025 [10]. - The gross profit margin for the subsidiary Suzhou Langkes is projected to be 23.20% for 2025, down from 28.39% in the previous year, indicating a decrease of 5.19 percentage points [10]. - The company's 3D printing business generated revenue of 2.67 million yuan in 2025, accounting for less than 0.2% of total revenue, which currently does not impact the main business significantly [10]. Group 4: Acquisition Plans - The company plans to acquire a 45% stake in Suzhou Langkes Precision Hardware Co., Ltd. through a share issuance and raise supporting funds, pending further decisions and approvals from relevant parties [4][11]. - The completion of due diligence, auditing, and evaluation for this transaction may face uncertainties regarding timing and regulatory approvals [11].